MSMercedes Segovia

Mercedes Segovia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mercedes Segovia has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Marcelo Hill

    Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo, 11400 Montevideo, Uruguay; Immunobiology Department, Faculty of Medicine, University of the Republic, 11800 Montevideo, Uruguay

    4 shared publications
  • Marcelo Hill

    Laboratory of Immunoregulation and Inflammation, Institut Pasteur Montevideo, Montevideo, Uruguay

    3 shared publications
  • Sofía Russo

    Laboratory of Immunoregulation and Inflammation, Institut Pasteur Montevideo, Montevideo, Uruguay

    3 shared publications
  • Daniela Olivera

    Laboratory of Immunoregulation and Inflammation, Institut Pasteur de Montevideo, 11400 Montevideo, Uruguay; Immunobiology Department, Faculty of Medicine, University of the Republic, 11800 Montevideo, Uruguay

    2 shared publications
  • Helena Pardo

    Laboratorio de Nanotecnología, Instituto Polo Tecnológico de Pando, Facultad de Química, Universidad de la República, Canelones 91000, Uruguay

    2 shared publications
  • Juan Pablo Tosar

    Functional Genomics Laboratory, Institut Pasteur de Montevideo

    2 shared publications

Latest Publications

  • Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival

    by Germán Bsc Galliussi, Javier Noboa, Alejandro Leyva, Sofía Russo, Lucía Msc Collela, Claire Bsc Usal, Mateo Malcuori, David Bsc Charbonnier, Carlos Escande, Gloria Virginia López, et al.

    Background.: Targeting emerging immunoregulatory molecules may open new therapeutic perspectives to control alloresponses and alleviate the burden of immunosuppressors. Transmembrane protein 176B (TMEM176B) is an intracellular cation channel highly expressed by myeloid cells. We have shown that TMEM176B is associated with allograft tolerance. Moreover, it controls the tolerogenic function of dendritic cells and inhibits NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. Here, we speculated that pharmacological activation of TMEM176B by the nitroalkene derivative of 5-(2-nitroethenyl) salicylic acid (SANA) may prolong allograft survival through active immunoregulatory mechanisms. Methods.: SANA impact on TMEM176B activity was studied in vitro and in vivo. We assessed the potential efficacy of SANA treatment in prolonging graft survival in 2 allograft models: a mouse skin model with minor mismatches and a rat heart model with fully mismatches. Wild type and Tmem176b −/− recipient mice were used. Graft survival and innate and adaptive immune response were analyzed at the skin graft and draining lymph nodes through flow cytometry studies. Results.: SANA was identified as an activator of TMEM176B-dependent ion transport. SANA prolongs allograft survival in a Tmem176b -dependent manner. SANA triggered the expression of the immunoregulatory enzyme heme oxygenase-1 in wild type but not in Tmem176b −/− MHCII + CD11c high CD11b + conventional dendritic cells within the graft. SANA therapy was associated with increased CD4 + Forkhead box P3 + regulatory T (Treg) in the graft. The heme oxygenase-1 inhibitor tin protoporphyrin IX completely blocked the effect of SANA on graft survival and Treg in vivo. Furthermore, Treg modulation by anti-CD3 antibodies improves the graft-protecting effect of SANA. Conclusions.: SANA-mediated activation of TMEM176B triggers an immunoregulatory pathway that prolongs skin and heart graft survival.

  • Open Access

    Ribonuclease activity undermines immune sensing of naked extracellular RNA

    by Mauricio Castellano, Valentina Blanco, Marco Li Calzi, Bruno Costa, Kenneth Witwer, Marcelo Hill, Alfonso Cayota, Mercedes Segovia, Juan Pablo Tosar


  • Formulating a TMEM176B blocker in chitosan nanoparticles uncouples its paradoxical roles in innate and adaptive antitumoral immunity

    by Sabina Victoria, Analía Castro, Alvaro Pittini, Daniela Olivera, Sofía Russo, Ignacio Cebrian, Alvaro W. Mombru, Eduardo Osinaga, Helena Pardo, Mercedes Segovia, et al.


  • Open Access

    Ribonuclease activity undermines immune sensing of naked extracellular RNA

    by Mauricio Castellano, Valentina Blanco, Marco Li Calzi, Bruno Costa, Kenneth Witwer, Marcelo Hill, Alfonso Cayota, Mercedes Segovia, Juan Pablo Tosar

    SUMMARY: The plasma membrane and the membrane of endosomal vesicles are considered physical barriers preventing extracellular RNA uptake. While naked RNA can be spontaneously internalized by certain cells types, functional delivery of naked RNA into the cytosol has been rarely observed. Here we show that extracellular ribonucleases, mainly derived from cell culture supplements, have so far hindered the study of extracellular RNA functionality. In the presence of active ribonuclease inhibitors (RI), naked bacterial RNA is pro-inflammatory when spiked in the media of dendritic cells and macrophages. In murine cells, this response mainly depends on the action of endosomal Toll-like receptors. However, we also show that naked RNA can perform endosomal escape and engage with cytosolic RNA sensors and ribosomes. For example, naked mRNAs encoding reporter proteins can be spontaneously internalized and translated by a variety of cell types, in an RI-dependent manner. In vivo, RI co-injection enhances the activation induced by naked extracellular RNA on splenic lymphocytes and myeloid-derived leukocytes. Furthermore, naked extracellular RNA is inherently pro-inflammatory in ribonuclease-poor compartments such as the peritoneal cavity. Overall, these results demonstrate that naked RNA is bioactive and does not need encapsulation inside synthetic or biological lipid vesicles for functional uptake, making a case for nonvesicular extracellular RNA-mediated intercellular communication.


  • Reverse Phase HPLC Methodology for the Determination of Bay K8644

    by Pablo Miranda, Analía Castro, Luisina Rodríguez Grassi, Danilo Davyt, Marcelo Hill, Mercedes Segovia, Alvaro W Mombrú, Helena Pardo

    Following ICH guidelines for analytical validation, we report a common C18 column stability indicating isocratic reverse phase high performance liquid chromatography method for the determination of the ion channel modulator Bay K8644. Two main forced degradation products and a minor impurity were also tentatively identified by Mass Spectrometry. The mobile phase consisted of a 50/50 acetonitrile/buffer mixture at a flow rate of 2 mL/min. Mean retention time for Bay K8644 was 3.030 minutes. Excellent linearity (r = 0.9998) was achieved in the range 0.10–1.40 μg/mL at 274 nm wavelength. Analytical limits were 16.56 ± 1.04 ng/mL for detection and 55.21 ± 3.48 ng/mL for quantitation respectively. Accuracy and precision studies showed good results (95–105%). Robustness was assessed by varying ±3%, both temperature and flow rate. Five different stress conditions were applied to assess Bay K8644’s stability. Only basic and photolytic treatments yielded degradation products, both correctly resolved in a total runtime of 4 minutes. In conclusion, we developed a fast, simple, sensitive, accurate, precise, reliable and stability indicating method for detecting/quantifying Bay K8644, and tentatively characterized its main impurities/forced degradation products.

  • Open Access

    The intracellular cation channel TMEM176B as a dual immunoregulator

    by Marcelo Hill, Sofía Russo, Daniela Olivera, Mateo Malcuori, Germán Galliussi, Mercedes Segovia

    Characterizing immune regulatory pathways is critical to understand physiological and pathophysiological processes as well as to identify novel immunotherapeutic targets. The cation channel TMEM176B has emerged in the last years as a potential new immunoregulatory player and pharmacological target. Here, we review how expression data, clinical associations of genetic variants and functional studies support a dual role for TMEM176B in regulating immune responses. Thus, TMEM176B can inhibit effector immune responses in some settings whereas it may also promote immunity by supporting antigen presentation in others. We also discuss a potential role for TMEM176B in regulating type 2 and 3 immunity and comment recent data on modulation of DC biology and inflammasome activation as well as CD8+ T cell responses. Understanding the role of TMEM176B in immunity is critical to propose rational pharmacological approaches targeting this channel.


  • Open Access

    PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease

    by Maite Duhalde Vega, Daniela Olivera, Gustavo Gastão Davanzo, Mauricio Bertullo, Verónica Noya, Gabriela Fabiano de Souza, Stéfanie Primon Muraro, Icaro Castro, Ana Paula Arévalo, Martina Crispo, et al.

    Severe COVID-19 is associated with hyperinflammation and weak T cell responses against SARS-CoV-2. However, the links between those processes remain partially characterized. Moreover, whether and how therapeutically manipulating T cells may benefit patients are unknown. Our genetic and pharmacological evidence demonstrates that the ion channel TMEM176B inhibited inflammasome activation triggered by SARS-CoV-2 and SARS-CoV-2–related murine β-coronavirus. Tmem176b −/− mice infected with murine β-coronavirus developed inflammasome-dependent T cell dysfunction and critical disease, which was controlled by modulating dysfunctional T cells with PD-1 blockers. In critical COVID-19, inflammasome activation correlated with dysfunctional T cells and low monocytic TMEM176B expression, whereas PD-L1 blockade rescued T cell functionality. Here, we mechanistically link T cell dysfunction and inflammation, supporting a cancer immunotherapy to reinforce T cell immunity in critical β-coronavirus disease.